These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 9521345)

  • 1. Does 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy exert a direct anti-ischemic effect?
    Di Napoli P; Barsotti A
    Circulation; 1998 Mar; 97(9):937. PubMed ID: 9521345
    [No Abstract]   [Full Text] [Related]  

  • 2. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors.
    Tobert JA
    Nat Rev Drug Discov; 2003 Jul; 2(7):517-26. PubMed ID: 12815379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
    J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein, coronary risk, and statins.
    Harv Womens Health Watch; 2001 Sep; 9(1):2. PubMed ID: 11572835
    [No Abstract]   [Full Text] [Related]  

  • 6. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
    McAnally JA; Gupta J; Sodhani S; Bravo L; Mo H
    Exp Biol Med (Maywood); 2007 Apr; 232(4):523-31. PubMed ID: 17392488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Rogers JD; Zhao J; Liu L; Amin RD; Gagliano KD; Porras AG; Blum RA; Wilson MF; Stepanavage M; Vega JM
    Clin Pharmacol Ther; 1999 Oct; 66(4):358-66. PubMed ID: 10546919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.
    Li W; Cui Y; Kushner SA; Brown RA; Jentsch JD; Frankland PW; Cannon TD; Silva AJ
    Curr Biol; 2005 Nov; 15(21):1961-7. PubMed ID: 16271875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expanding role of HMG-CoA reductase inhibitors (statins) in the prevention and treatment of ischemic heart disease.
    Chilton R; O'Rourke RA
    Curr Probl Cardiol; 2001 Dec; 26(12):734-64. PubMed ID: 11743453
    [No Abstract]   [Full Text] [Related]  

  • 11. The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, lovastatin (statin) ameliorates CCK-induced acute pancreatitis in rats.
    Choi OS; Park SJ; Seo SW; Park CS; Cho JJ; Ahn HJ
    Biol Pharm Bull; 2005 Aug; 28(8):1394-7. PubMed ID: 16079481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reported use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors was not associated with reduced recurrence of colorectal adenomas.
    Wei JT; Mott LA; Baron JA; Sandler RS;
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1026-7. PubMed ID: 15824186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful use of an HMG-CoA reductase inhibitor as adjunctive therapy in the management of refractory bile leak complicating laparoscopic cholecystectomy.
    Rabine J; Jones MP
    Am J Gastroenterol; 1998 Dec; 93(12):2602-3. PubMed ID: 9860442
    [No Abstract]   [Full Text] [Related]  

  • 14. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9.
    Viedt C; Shen W; Fei J; Kamimura M; Hänsch GM; Katus HA; Kreuzer J
    Basic Res Cardiol; 2003 Nov; 98(6):353-61. PubMed ID: 14556080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy.
    Ramasubbu K; Estep J; White DL; Deswal A; Mann DL
    J Am Coll Cardiol; 2008 Jan; 51(4):415-26. PubMed ID: 18222351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lovastatin attenuates nerve injury in an animal model of Guillain-Barré syndrome.
    Sarkey JP; Richards MP; Stubbs EB
    J Neurochem; 2007 Mar; 100(5):1265-77. PubMed ID: 17286627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioconversion of lovastatin to a novel statin by Amycolatopsis sp.
    Zhuge B; Fang HY; Yu H; Rao ZM; Shen W; Song J; Zhuge J
    Appl Microbiol Biotechnol; 2008 May; 79(2):209-16. PubMed ID: 18368405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward a role for statins in immunomodulation.
    Mach F
    Mol Interv; 2002 Dec; 2(8):478-80. PubMed ID: 14993398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of the HMG-CoA reductase inhibitor lovastatin and nitric oxide in cardiomyocyte cell death.
    Rabkin SW; Tsang MY
    Pharmacology; 2008; 82(1):74-82. PubMed ID: 18504415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin.
    Kohno H; Sakai T; Saito S; Okano K; Kitahara K
    Exp Eye Res; 2007 Mar; 84(3):569-76. PubMed ID: 17208229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.